In the last decade adenovirus (AdV) vectors have emerged as promising technology in gene therapy. They have been used for genetic modification of a variety of somatic cells in vitro and in vivo. They have been widely used as gene delivery vectors in experiments both with curative and preventive purposes. AdV vectors have been used in the experimental and in some extent in the clinical gene therapy of a variety of cancers. The combination of recombinant AdV technology with chemotherapy (pro drug system) seems to be promising, too. AdV vectors offer several advantages over other vectors. Replication defective vectors can be produced in very high titers (1011 pfu/ml) thus allowing a substantially greater efficiency of direct gene transfer; they have the capacity to infect both replicating and nonreplicating (quiescent) cells from a variety of tissues and species. Several important limitations of adenovirus mediated gene transfer are also known, such as the relatively short-term (transient) expression of foreign genes, induction of the host humoral and cellular immune response to viral proteins and viral infected cells, which may substantially inhibit the effect of repeated treatment with AdV vectors, the limited cloning capacity and the lack of target cell specificity. However, the well-understood structure, molecular biology and host cell interactions of AdV-s offer some potential solutions to these limitations.
Hitt, M. M., Graham, F. L.: Adenovirus vectors for human gene therapy. Adv Virus Res 55, 479 (2000)
'Adenovirus vectors for human gene therapy ' () 55 Adv Virus Res : 479.
Kulcsár, G., Csata, S., Nász, I.: Isolation of an infectious oncogenic adenovirus strain from the stimulated lymphocytes of a patient with bladder tumor. Acta Microbiol Hung 38, 91 (1991)
'Isolation of an infectious oncogenic adenovirus strain from the stimulated lymphocytes of a patient with bladder tumor ' () 38 Acta Microbiol Hung : 91.
Csata, S., Kulcsár, G., Dán, P., Horváth, J., Nász, I.: Adenovirus antibodies in tumorous diseases of the urogenital system. Acta Chirurg Acad Sci Hung 23, 15 (1982)
'Adenovirus antibodies in tumorous diseases of the urogenital system ' () 23 Acta Chirurg Acad Sci Hung : 15.
Russel, W. C., Adrian, T., Bartha, A., Fujinaga, K., Ginsberg, H. S., Hierholzer, J. C., de Jong, J. C., Li, Q. G., Mautner, V., Nász, I., Wadell, G.: Adenoviridae. In: Virus taxonomy. Sixth report of the International Committee on Taxonomy of Viruses. Eds.: Murphy, F. A., Fauquet, C. M., Bishop, D. H. L.: Arch Virol Suppl 10, 128 (1996)
Trask, T. W., Trask, R. P., Augilar-Cordova, E., Shine, H. D., Wyde, P. R., Goodman, J. C., Hamilton, W. J., Rojas-Martinez, A., Chen, S. H., Woo, S. L., Grossman, R. G.: Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 1, 195 (2000)
'Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors ' () 1 Mol Ther : 195.
Randrianarison-Jewtoukoff, V., Perricaudet, M.: Recombinant adeno-viruses as vaccines. Biologicals 23, 145 (1995)
'Recombinant adeno-viruses as vaccines ' () 23 Biologicals : 145.
Berkner, K. L.: Development of adenovirus vectors for the expression of heterologous genes. Bio Techniques 6, 616 (1986)
'Development of adenovirus vectors for the expression of heterologous genes ' () 6 Bio Techniques : 616.
Lee, M. G., Abina, M. A., Perricaudet, M.: The constitutive expression of the immunomodulatory gp 19k protein in E1-, E3-adenoviral vectors strongly reduces the host T cell response against the vector. Gene Ther 2, 256 (1995)
'The constitutive expression of the immunomodulatory gp 19k protein in E1-, E3-adenoviral vectors strongly reduces the host T cell response against the vector ' () 2 Gene Ther : 256.
Stewart, AK., Lassam, N. J., Quirt, I. C., Bailey, D. J., Roststein, L. E., Krajden, M., Dessureault, S., Gallinger, S., Cappe, D., Wan, Y., Addison, C. L., Moen, R. C., Gauldie, J., Graham, F. L.: Adenoviralmediated gene delivery of interleukin-2 in metastatic breath cancer and melanoma: results of a phase I clinical trial. Gene Ther 6, 350 (1999)
'Adenoviralmediated gene delivery of interleukin-2 in metastatic breath cancer and melanoma: results of a phase I clinical trial ' () 6 Gene Ther : 350.
Wilson, J. M.: Gene therapy for cystic fibrosis: challenges and future directions. J Clin Invest 96, 2547 (1995)
'Gene therapy for cystic fibrosis: challenges and future directions ' () 96 J Clin Invest : 2547.
Alvarez, R. D., Gomez-Navarro, J., Wand, M., Barnes, M. N., Strong, T. V., Arani, R. B., Arafat, W., Hughes, J. V., Siegal, G. P., Curiel, D. T.: Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther 2, 524 (2000)
'Adenoviral-mediated suicide gene therapy for ovarian cancer ' () 2 Mol Ther : 524.
Hasenburg, A., Tong, X. W., Rojas-Martinez, A., Nyberg-Hoffman, C., Kieback, C. C., Kaplan, A., Kaufman, R. H., Ramzy, I., Augilar-Cordova, E., Kieback, D. G.: Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer. Cancer Gene Ther 7, 839 (2000)
'Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer ' () 7 Cancer Gene Ther : 839.
Sandmair, A. M., Loimas, S., Puranen, P., Immonen, A., Kossila, M., Puranen, M., Hurskainen, H., Tyynela, K., Turunen, M., Vanninen, R., Lehtolainen, P., Paljarvi, L., Johanson, R., Vapalahti, M., Yla-Herttula, S.: Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 11, 2197 (2000)
'Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses ' () 11 Hum Gene Ther : 2197.
Graham, F. L., Smiley, J., Russel, W. C., Nairn, R.: Characteristics of a human cell line transformed by DNA from human adenovirus type 5. Virology 186, 59 (1977)
'Characteristics of a human cell line transformed by DNA from human adenovirus type 5 ' () 186 Virology : 59.
Davis, A. R., Meyers, K., Wilson, J. M.: High throughput method for creating and screening recombinant adenoviruses. Gene Ther 5, 1148 (1998)
'High throughput method for creating and screening recombinant adenoviruses ' () 5 Gene Ther : 1148.
Hitt, M. M., Addison, C. L., Graham, F. L.: Human adenovirus vectors for gene transfer into mammalian cells. In: Advances in Pharmacology, Ed.: August, T. 40, 137 (1997)
Gabaglia, C. R., Pedersen, B., Hitt, M., Burdin, N., Sercarz, E. E., Graham, F. L., Gauldie, J., Braciak, T. A.: A single intramuscular injection with an adenovirus-expressing IL-12 protects BALB/c mice against Leishmania major infection, while treatment with an IL-4-expressing vector increases disease susceptibility in B10D2 mice. J Immunol 162, 753 (1999)
'A single intramuscular injection with an adenovirus-expressing IL-12 protects BALB/c mice against Leishmania major infection, while treatment with an IL-4-expressing vector increases disease susceptibility in B10D2 mice ' () 162 J Immunol : 753.
Old, J. L.: Immunotherapy for cancer. Sci Am 275, 102 (1996)
'Immunotherapy for cancer ' () 275 Sci Am : 102.
Lin, P., Buxton, J. A., Acheson, A., Radziejewski, C., Maisonpierra, P. C., Yancopoulos, G. D., Channon, K. M., Hale, L. P., Dewhirst, M. W., George, S. E., Peters, K. G.: Antiangiogenic gene therapy targeting the endothelium-specific tyrosine kinase Tie2. Proc Natl Acad Sci USA 95, 8829 (1998)
'Antiangiogenic gene therapy targeting the endothelium-specific tyrosine kinase Tie2 ' () 95 Proc Natl Acad Sci USA : 8829.
Kafri, T., Morgan, D., Krahl, T., Sarvetnick, N., Sherman, L., Verma, I.: Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression. Pro Natl Acad Sci USA 95, 11377 (1998)
'Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression ' () 95 Pro Natl Acad Sci USA : 11377.
Smith, T. A., White, B., Gardner, J. M., Kaleko, M., McClelland, A.: Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther 3, 496 (1996)
'Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector ' () 3 Gene Ther : 496.
Kong, H. L., Hecht, D., Song, W., Kovesdi, I., Hackett, N. R., Yayon, A., Crystal, R. G.: Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted from of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther 9, 823 (1998)
'Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted from of the extracellular domain of the flt-1 vascular endothelial growth factor receptor ' () 9 Hum Gene Ther : 823.
Wivel, N. A., Gao, G-P., Wilson, J. M.: Adenovirus vectors. In: The development of human gene therapy Ed: Friedman, T. 87, Cold Spring Harbor Lab Press, San Diego, CA (1999)
The development of human gene therapy , () 87.
Yang, Y., Trinchieri, G., Wilson, J. M.: Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med 1, 890 (1995)
'Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung ' () 1 Nat Med : 890.
Mastrangeli, A., Harvey, B. G., Yao, J., Wolff, G., Kovesdi, I., Crystal, R. G., Falck-Pedersen, E.: "Sero-switch" adenovirus mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defense against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther 7, 79 (1996)
'"Sero-switch" adenovirus mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defense against repeat adenovirus vector administration by changing the adenovirus serotype ' () 7 Hum Gene Ther : 79.
Mack, C. A., Song, W. R., Carpenter, H., Wickham, T. J., Kovesdi, I., Harvey, B. G., Magovern, C. J., Isom, O. W., Rosengart, T., Falck-Pedersen, E., Hackett, N. R., Crystal, R. G., Mastrangeli, A.: Circumvention ofanti-adenovirus neutralising immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 8, 99 (1997)
'Circumvention ofanti-adenovirus neutralising immunity by administration of an adenoviral vector of an alternate serotype ' () 8 Hum Gene Ther : 99.
Ádám, É., Nász, I., Lengeyel, A.: Characterization of adenovirus hexons by their epitope composition. Arch Virol 141, 1891 (1996)
'Characterization of adenovirus hexons by their epitope composition ' () 141 Arch Virol : 1891.
Ádám, É., Nász, I., Hudecz, F., Lengyel, A., Mezö, G., Dobay, O.: Characterization of intertype specific epitopes on adenovirus hexons. Arch Virol 43, 1669 (1998)
'Characterization of intertype specific epitopes on adenovirus hexons ' () 43 Arch Virol : 1669.
Nász, I., Ádám, É., Lengyel, A.: Alternate adenovirus type-pairs for a possible circumvention of host immune response to recombinant adenovirus vectors. Acta Microbiol Immunol Hung 48, 141 (2001)
'Alternate adenovirus type-pairs for a possible circumvention of host immune response to recombinant adenovirus vectors ' () 48 Acta Microbiol Immunol Hung : 141.
Imler, J. L., Chartier, C., Dreyer, D., Dieterlé, A., Saintemarie, M., Faure, T., Pavirani, A., Mehtali, M.: Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors. Gene Ther 3, 75 (1996)
'Novel complementation cell lines derived from human lung carcinoma A549 cells support the growth of E1-deleted adenovirus vectors ' () 3 Gene Ther : 75.
Kochanek, S., Clemens, P., Mitani, K., Chen, H-H., Chan, S., Caskey, C. T.: A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase. Proc Natl Acad Sci USA 93, 5731 (1996)
'A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and β-galactosidase ' () 93 Proc Natl Acad Sci USA : 5731.
Lieber, A., He, C. Y., Kay, M. A.: Adenoviral preterminal protein stabilizes mini-adenoviral genomes in vitro and in vivo. Nat Biotechnol 15, 1383 (1997)
'Adenoviral preterminal protein stabilizes mini-adenoviral genomes in vitro and in vivo ' () 15 Nat Biotechnol : 1383.
Hardy, S., Kitamura, M., Harris-Stansil, T., Dai, Y., Phipps, M. L.: Construction of adenovirus vectors through Cre.lox recombination. J Virol 71, 1842 (1997)
'Construction of adenovirus vectors through Cre.lox recombination ' () 71 J Virol : 1842.
Hitt, M. M., Parks, R. J., Graham, F. L.: Structure and genetic organization of adenovirus vectors. In: The development of human gene therapy Ed: Friedman, T. 61, Cold Spring Harbor Lab Press, Cold Spring Harbor, N. Y. (1999)
The development of human gene therapy , ().
Chirmule, N., Hughes, J. V., Gao, G. P., Raper, S. E., Wilson, J. M.: Role of E4 in eliciting CD4 T-cell and B-cell responses to adenovirus vectors delivered to murine and nonhuman primate lungs. J Virol 72, 6138 (1998)
'Role of E4 in eliciting CD4 T-cell and B-cell responses to adenovirus vectors delivered to murine and nonhuman primate lungs ' () 72 J Virol : 6138.
Brough, D. E., Hsu, C., Kulesa, V. A., Lee, G. M., Cantolupo, L. J., Lizonova, A., Kovesdi, I.: Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo. J Virol 71, 9206 (1997)
'Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo ' () 71 J Virol : 9206.
Morral, N., O'Neal, W., Rice, K., Leland, M., Kaplan, J., Piedra, P. A., Zhou, H., Parks, R., Velji, R., Aguilar-Cordova, E., Wadsworth, S., Graham, F., Kochanek, S., Carey, K. D., Beaudet, A. L.: Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 96, 12816 (1999)
'Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons ' () 96 Proc Natl Acad Sci USA : 12816.
Parks, R. J., Evelegh, C., Graham, F. L.: Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Ther 6, 1565 (1999)
'Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration ' () 6 Gene Ther : 1565.
Bilbao, G., Feng, M., Rancourt, C., Jackson, W. H., Curiel, D. T.: Adenoviral/retroviral vector chimeras: A novel strategy to achieve high-efficiency stable transduction in vivo. FASEB J 11, 624 (1997)
'Adenoviral/retroviral vector chimeras: A novel strategy to achieve high-efficiency stable transduction in vivo ' () 11 FASEB J : 624.
Rodrigues, E. G., Zavala, F., Nussenzweig, R. S., Wilson, J. M., Tsuji, M.: Efficient induction of protective anti-malaria immunity by recombinant adenovirus. Vaccine 16, 1812 (1998)
'Efficient induction of protective anti-malaria immunity by recombinant adenovirus ' () 16 Vaccine : 1812.
Michael, S., Hong, J., Curiel, D., Engler, J. A.: Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther 2, 660 (1995)
'Addition of a short peptide ligand to the adenovirus fiber protein ' () 2 Gene Ther : 660.
Recchia, A., Parks, R. J., Lamartina, S., Toniatti, C., Pieroni, L., Palombo, F., Ciliberto, G., Graham, F. L., Cortese, R., La Monica, N., Colloca, S.: Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc Natl Acad Sci USA 96, 2615 (1999)
'Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector ' () 96 Proc Natl Acad Sci USA : 2615.
Fisher, K. J., Kelley, W. M., Burda, J. F., Wilson, J. M.: A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome. Hum Gene Ther 7, 2079 (1996)
'A novel adenovirus-adeno-associated virus hybrid vector that displays efficient rescue and delivery of the AAV genome ' () 7 Hum Gene Ther : 2079.
Samulski, R. J., Zhu, X., Xias, X.: Targeted integration of adeno-associated virus (AAV) into human chromosome 19. Published erratum appears in EMBO J 11, 1228 (1992). EMBO J 10, 3941 (1991)
'Targeted integration of adeno-associated virus (AAV) into human chromosome 19. Published erratum appears in EMBO J 11, 1228 (1992) ' () 10 EMBO J : 3941.
Krasnykh, V. N., Mikheeva, G. V., Douglas, J. T.: Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 70, 6839 (1996)
'Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism ' () 70 J Virol : 6839.
Douglas, J. T., Curiel, D. T.: Adenoviruses as vectors for gene therapy. Science and Medicine 4, 44 (1997)
'Adenoviruses as vectors for gene therapy ' () 4 Science and Medicine : 44.
Douglas, J. T., Rogers, B. E., Rosenfeld, M. E.: Targeted gene delivery by tropism-modified adenoviral vector. Nat Biotechn 14, 1574 (1996)
'Targeted gene delivery by tropism-modified adenoviral vector ' () 14 Nat Biotechn : 1574.
Rancourt, C., Rogers, B. E., Sosnowski, B. A., Wang, M., Piche, A., Frincke, J., Curiel, D. T.: Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin Cancer Res 4, 2455 (1998)
'Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer ' () 4 Clin Cancer Res : 2455.
Krasnykh, V., Dmitriev, I., Mikheeva, G., Miller, C. R., Belousova, N., Curiel, D. T.: Characterization of an adenovirus vector containing a heterologous peptide in the HI loop of the fiber knob. J Virol 72, 1844, (1998)
'Characterization of an adenovirus vector containing a heterologous peptide in the HI loop of the fiber knob ' () 72 J Virol : 1844.
Wickham, T. J., Carrion, M. E., Kovesdi, I.: Targeting of adenovirus penton base to new receptors through replacement of its GRD motif with other receptor-specific motifs. Gene Ther 2, 750 (1995)
'Targeting of adenovirus penton base to new receptors through replacement of its GRD motif with other receptor-specific motifs ' () 2 Gene Ther : 750.
Wickham, T. J., Segal, D. M., Roelvink, P. W.: Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 70, 6831 (1996)
'Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies ' () 70 J Virol : 6831.
Wickham, T. J., Haskard, D., Segal, D., Kovesdi, I.: Targeting endothelium for gene therapy via receptors up-regulated during angiogenesis and inflammation. Cancer Immunol Immunother 45, 149 (1997)
'Targeting endothelium for gene therapy via receptors up-regulated during angiogenesis and inflammation ' () 45 Cancer Immunol Immunother : 149.
Nász, I., Ádám, É.,: New developments and trends in the adenovirus research (in Hungarian with English summary). Orv Hetil 138, 27 (1997)
'New developments and trends in the adenovirus research (in Hungarian with English summary) ' () 138 Orv Hetil : 27.
Tournier-Lasserve, E.: Gene therapy and beyond. Lancet 354, 22 (2000)
'Gene therapy and beyond ' () 354 Lancet : 22.
Romano, G., Michell, P., Pacilio, C., Giordano, A.: Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications. Stem Cells 18, 19 (2000)
'Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications ' () 18 Stem Cells : 19.
Crystal, R. G., Jaffe, A., Brody, S., Mastrangeli, A., McElvaney, N. G., Rosenfeld, M., Chu, C-S., Danel, C., Hay, J., Eissa, T.: A phase I study in cytic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic fibrosis transmembrane conductance regulator gene in the lung. Hum Gene Ther 6, 643 (1995)
'A phase I study in cytic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic fibrosis transmembrane conductance regulator gene in the lung ' () 6 Hum Gene Ther : 643.
Boucher, R., Knowles, M., Johnson, L., Olsen, J., Pickles, R., Wilson, J., Engelhardt, J., Yang, Y., Grossman, M.: Gene therapy for cystic fibrosis using E1-deleted adenovirus: a phase 1 trial in the nasal cavity. Hum Gene Ther 5, 615 (1994)
'Gene therapy for cystic fibrosis using E1-deleted adenovirus: a phase 1 trial in the nasal cavity ' () 5 Hum Gene Ther : 615.
Wilott, R. W., Whitsett, J., Trapnell, B.: A phase I study of gene therapy of cystic fibrosis utilizing a replication deficient recombinant adenovirus vector to deliver the human cystic fibrosis transmembrane conductance regulator cDNA to the airways. In: Federal Register 58, 21737 (1995)
Perricone, M. A., Rees, D. D., Sacks, C. R., Smith, K. A., Kaplan, J. M., St George, J. A.: Inhibitory effect of cystic fibrosis sputum on Adenovirus Mediated gene transfere in cultured epithelial cells. Hum Gene Ther 11, 1997 (2000)
'Inhibitory effect of cystic fibrosis sputum on Adenovirus Mediated gene transfere in cultured epithelial cells ' () 11 Hum Gene Ther : 1997.
Marchand-Pinatel, S., Planells, R., Merten, M. D., Kammouni, W., Figarella, C.: A quantitative multistandard reverse transcriptase-polymerase chain reaction assay of the cystic fibrosis transmembrane conductance regulate: its usefulness in studying efficiency of gene transfere. Anal Biochem 283, 200 (2000)
'A quantitative multistandard reverse transcriptase-polymerase chain reaction assay of the cystic fibrosis transmembrane conductance regulate: its usefulness in studying efficiency of gene transfere ' () 283 Anal Biochem : 200.
Chrimule, N., Propert, K., Magosin, S., Qian, Y., Qian, R., Wilson, J.: Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6, 1574 (1999)
'Immune responses to adenovirus and adeno-associated virus in humans ' () 6 Gene Ther : 1574.
Rochat, T.: Somatic gene therapy of mucoviscidosis using recombinant adenovirus: the start of a long course. Schweiz Med Wochenschr 127, 148 (1997)
'Somatic gene therapy of mucoviscidosis using recombinant adenovirus: the start of a long course ' () 127 Schweiz Med Wochenschr : 148.
Harvey, B. G., Leopold, P. L., Hackett, N. R., Grasso, T. M., Williams, P. M., Tucker, A. L., Kaner, R. J., Ferris, B., Gonda, I., Sweeney, T. D., Ramalingam, R., Kovesdi, I., Shak, S., Crystal, R. G.: Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J Clin Invest 10, 1245 (1999)
'Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus ' () 10 J Clin Invest : 1245.
Marchisone, C., Pfeffer, U., Del Grosso, F., Noonan, D. M., Santi, L., Albini, A.: Progress towards gene therapy for cancer. J Exp Clin Cancer Res 19, 261 (2000)
'Progress towards gene therapy for cancer ' () 19 J Exp Clin Cancer Res : 261.
Dachs, G. U., Dougherty, G. J., Stratford, I. J., Chaplin, D. J.: Targeting gene therapy to cancer: a review. Oncol Res 9, 313 (1997)
'Targeting gene therapy to cancer: a review ' () 9 Oncol Res : 313.
O'Malley, B. W. Jr., Couch, M. E.: Gene therapy and strategies for head and neck cancer. Adv Otorhinolaryngol 56, 279 (2000)
'Gene therapy and strategies for head and neck cancer ' () 56 Adv Otorhinolaryngol : 279.
Clayman, G. L., Frank, D. K., Bruso, P. A., Gopfert, H.: Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res 5, 1715 (1999)
'Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers ' () 5 Clin Cancer Res : 1715.
Crystal, R. G.: In vivo and ex vivo gene therapy strategies to treat tumors using adnovirus gene transfere vectors. Cancer Chemother 43 Suppl, S90 (1999)
'In vivo and ex vivo gene therapy strategies to treat tumors using adnovirus gene transfere vectors ' () 43 Cancer Chemother : S90.
Alemany, R., Gomez-Manzano, C., Balague, C., Yung, W. K., Curiel, D. T., Kyritsis, A. P., Fueyo, J.: Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res 252, 1 (1999)
'Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses ' () 252 Exp Cell Res : 1.
Clayman, G. L., Dreiling, L.: Local delivery for gene therapy. Curr Oncol Rep 1, 138 (1999)
'Local delivery for gene therapy ' () 1 Curr Oncol Rep : 138.
Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., Randlev, B., Gillenwater, A. M., Bruso, P., Kaye, S. B., Hong, W. K., Kirn, D. H.: A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6, 879 (2000)
'A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer ' () 6 Nat Med : 879.
Morris, J. C., Ramsey, W. J., Wildner, O., Muslow, H. A., Aguilar-Cordova, E., Blease, R. M.: A phase I study of intralesional administration of an adenovirus vector expressing the HS-1 thymidine kinase gene (AdV. RSV. TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma. Hum Gene Ther 11, 487 (2000)
'A phase I study of intralesional administration of an adenovirus vector expressing the HS-1 thymidine kinase gene (AdV. RSV. TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma ' () 11 Hum Gene Ther : 487.
Boulay, J. L., Perruchoud, A. P., Reuter, J., Bollinger, C., Herrmann, R., Rochlitz, C.: P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients. Cancer Gene Ther 7, 1215 (2000)
'P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients ' () 7 Cancer Gene Ther : 1215.
Swisher, S. G., Roth, J. A., Nemunaitis, J., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Connors, D. G., El-Naggar, A. K., Fossella, F., Glisson, B. S., Hong, W. K., Khuri, F. R., Kurie, J. M., Lee, J. J., Lee, J. S., Mack, M., Merritt, J. A., Nguyen, D. M., Nesbitt, J. C., Perez-Soler, R., Pisters, K. M., Putnam, J. B., Richli, W. R., Savin, M., Waugh, M. K.: Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 91, 763 (1999)
'Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer ' () 91 J Natl Cancer Inst : 763.
Schuler, M., Rochlitz, C., Horowitz, J. A., Schlegel, J., Perruchoud, A. P., Kommoss, F., Bollinger, C. T., Kauczor, H. U., Dalquen, P., Fritz, M. A., Swanson, S., Herrmann, R., Huber, C.: A phase I study of adenovirus-mediated wild-type p53 gene transfere in patients with advanced non-small-cell lung cancer. Hum Gene Ther 9, 2075 (1998)
'A phase I study of adenovirus-mediated wild-type p53 gene transfere in patients with advanced non-small-cell lung cancer ' () 9 Hum Gene Ther : 2075.
Roth, J. A., Swisher, S. G., Merrit, J. A., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., El-Naggar, A. K., Fossela, F. V., Glisson, B. S., Hong, W. K., Khurl, F. R., Kurie, J. M., Nesbitt, J. C., Pisters, K., Putman, J. B., Schrump, D. S., Shin, D. M., Walsh, G. L.: Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 replacement. Semin Oncol 25, 33 (1998)
'Gene therapy for non-small cell lung cancer: a preliminary report of a phase I trial of adenoviral p53 replacement ' () 25 Semin Oncol : 33.
Rosenfeld, M. A., Yoshimura, K., Trapnell, B. C., Yoneyama, K., Rosenthal, E. R., Dalemans, W., Fukayama, M., Bargon, J., Stier, L. E., Stratford-Perricaudet, L.: In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68, 143 (1992)
'In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium ' () 68 Cell : 143.
Wilson, J., Engelhardt, J., Grossman, M., Simon, R., Yang, Y.: Gene therapy of cystic fibrosis lung disease using E1 deleted adenoviruses: phase 1 trial. Hum Gene Ther 5, 501 (1994)
'Gene therapy of cystic fibrosis lung disease using E1 deleted adenoviruses: phase 1 trial ' () 5 Hum Gene Ther : 501.
Molinier-Frenkel, V., Boulaire, C. L., Gal, F. A., Gahery-Segard, H., Tursz, T., Guillett, J. G., Farace, F.: Longitudinal follow-up of cellular and humoral immunity induced by recombinant adenovirus-mediated gene therapy in cancer patients. Hum Gene Ther 11, 1911 (2000)
'Longitudinal follow-up of cellular and humoral immunity induced by recombinant adenovirus-mediated gene therapy in cancer patients ' () 11 Hum Gene Ther : 1911.
Wierda, W. G., Cantwell, M. J., Woods, S. J., Rassenti, L. Z., Prussak, C. E., Kipps, T. J.: CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96, 2917 (2000)
'CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia ' () 96 Blood : 2917.
Yen, N., loannides, C. G., Xu, K., Swisher, S. G., Lawrence, D. D., Kemp, B. L., El-Naggar, A. K., Cristiano, R. J., Fang, B., Glisson, B. S., Hong, W. K., Khuri, J. M., Lee, J. J, Lee, J. S., Merritt, J. A., Mukhopadhyay, T., Nesbitt, J. C., Nguyen, D., Perez-Soler, R., Pisters, M., Putnam, B. Jr., Schrump, D. S., Shin, D. M., Walsh, G. L., Roth, J. A.: Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. Cancer Gene Ther 7, 530 (2000)
'Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type ' () 7 Cancer Gene Ther : 530.
Sterman, D. H., Treat, J., Litzky, L. A., Amin, K. M., Coonrod, L., Molnar-Kimber, K., Recio, A., Knox, L., Wilson, J. M., Albelda, S. M., Kaiser, L. R.: Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of phase I clinical trial in malignant mesothelioma. Hum Gene Ther 9, 1083 (1998)
'Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of phase I clinical trial in malignant mesothelioma ' () 9 Hum Gene Ther : 1083.
Yeh, P., Perricaudet, M.: Advances in adenoviral vectors: from genetic engineering to their biology. FASEB J 11, 615 (1997)
'Advances in adenoviral vectors: from genetic engineering to their biology ' () 11 FASEB J : 615.
Engelhardt, J. F., Ye, X., Doranz, B., Wilson, J. M.: Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 91, 6196 (1994)
'Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver ' () 91 Proc Natl Acad Sci USA : 6196.
Molnar-Kimber, K. L., Sterman, D. H., Chang, M., Kang, E. H., ElBash, M., Lanuti, M., Elshami, A., Gelfand, K., Wilson, J. M., Kaiser, L. R., Albelda, S. M.: Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 9, 2121 (1998)
'Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma ' () 9 Hum Gene Ther : 2121.
Marshal, E.: Gene therapy death prompts review of adenovirus vector. Science 286, 2244 (1999)
'Gene therapy death prompts review of adenovirus vector ' () 286 Science : 2244.
Gao, G. P., Yang, Y., Wilson, J. M.: Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 70, 8934 (1996)
'Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy ' () 70 J Virol : 8934.
Krougliak, V., Graham, F. L.: Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Hum Gene Ther 6, 1575 (1995)
'Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants ' () 6 Hum Gene Ther : 1575.
Barnes, M. N., Pustilnik, T. B.: Current strategies in gene therapy for ovarian cancer. Curr Opin Obstet Gynecol 13, 47 (2001)
'Current strategies in gene therapy for ovarian cancer ' () 13 Curr Opin Obstet Gynecol : 47.
Habib, N. A., Sarraf, C. E., Mitry, R. R., Havlik, R., Nicholls, J., Kelly, M., Vernin, C. C., Gueret-Wardle, D., El-Masry, R., Salama, H., Ahmed, R., Michail, N., Edward, E., Jensen, S. L.: E1B-deleted adenovirus (d11520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther 12, 219 (2001)
'E1B-deleted adenovirus (d11520) gene therapy for patients with primary and secondary liver tumors ' () 12 Hum Gene Ther : 219.
Hasenburg, A., Tong, X. W., Rojas-Martinez, A., Nyberg-Hoffman, C., Kievack, C. C., Kaplan, A. L., Kaufman, R. H., Ramzy, I., Aguilar-Cordova, E., Kieback, D. G.: Thymidine kinase (TK) gene therapy of solid tumors: valacyclovir facilities outpatient treatment. Anticancer Res 19, 2163 (1999)
'Thymidine kinase (TK) gene therapy of solid tumors: valacyclovir facilities outpatient treatment ' () 19 Anticancer Res : 2163.
Pagliaro, L. C.: Gene therapy for bladder cancer. World J Urol 18, 148 (2000)
'Gene therapy for bladder cancer ' () 18 World J Urol : 148.
Sweeney, P., Pisters, L. L.: Ad5CMVp53 gene therapy for locally advanced prostate cancer - where do we stand? World J Urol 18, 121 (2000)
'Ad5CMVp53 gene therapy for locally advanced prostate cancer - where do we stand? ' () 18 World J Urol : 121.
Allay, J. A., Steiner, M. S., Zhang, Y., Reed, C. P., Cockroft, J., Lu, Y.: Adenovirus p16 gene therapy for prostate cancer. World J Urol 18, 111 (2000)
'Adenovirus p16 gene therapy for prostate cancer ' () 18 World J Urol : 111.
Herman, J. R., Adler, H. L., Aguilar-Cardova, E., Rojas-Martinez, A., Woo, S., Timme, T. L., Wheeler, T. M., Thompson, T. C., Scardino, P. T.: In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 10, 1239 (1999)
'In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial ' () 10 Hum Gene Ther : 1239.
O'Brien, T., Simari, R. D.: Gene therapy for atherosclerotic cardiovascular disease: a time for optimism and caution. Mayo Clin Pro 75, 831 (2000)
'Gene therapy for atherosclerotic cardiovascular disease: a time for optimism and caution ' () 75 Mayo Clin Pro : 831.
Alvarez, R. D., Barnes, M. N., Gomez-Navarro, J., Wang, M., String, T. V., Arafat, R. B., Johnson, M. R., Roberts, B. L., Siegal, G. P., Curiel, D. T.: A cancer gene therapy approach utilizing an anti-erb-2 single chain antibody-encoding adenovirus (Ad21): a phase I trial. Clin Cancer Res 6, 3081 (2000)
'A cancer gene therapy approach utilizing an anti-erb-2 single chain antibody-encoding adenovirus (Ad21): a phase I trial ' () 6 Clin Cancer Res : 3081.
Shalev, M., Kadmon, D., Teh, B. S., Butler, E. B., Aguiler-Cordova, E., Thompson, T. C., Herman, J. R., Adler, H. L., Scardino, P. T., Miles, B. J.: Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol 163, 1747 (2000)
'Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer ' () 163 J Urol : 1747.
Leppard, K. N.: E4 gene function in adenovirus, adenovirus vector and adeno-associated virus infection. J Gen Virol 78, 2131 (1997)
'E4 gene function in adenovirus, adenovirus vector and adeno-associated virus infection ' () 78 J Gen Virol : 2131.
Lahti, K. G., Vale, P. R., Losordo, D. W., Cespedes, R. M., Symes, J. F., Esakof, D. D., Maysky, M., Isner, J. M.: Gene therapy with vascular endothelial growth factor for inoperable coronary disease: anesthetic management and results. Anesth Analg 92, 19 (2001)
'Gene therapy with vascular endothelial growth factor for inoperable coronary disease: anesthetic management and results ' () 92 Anesth Analg : 19.
Crombleholme, T. M.: Adenoviral-mediated gene transfer in wound healing. Wound Repair Regen 8, 460 (2000)
'Adenoviral-mediated gene transfer in wound healing ' () 8 Wound Repair Regen : 460.
Margolis, D. J., Crombleholme, T., Herlyn, M.: Clinical protocol: phase I trial to evaluate the safety of H5.020CMV. PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound Repair Regen 8, 480 (2000)
'Clinical protocol: phase I trial to evaluate the safety of H5.020CMV. PDGF-B for the treatment of a diabetic insensate foot ulcer ' () 8 Wound Repair Regen : 480.
Chandler, L. A., Ma, C., Gonzalez, M. A., Doukas, J., Nguyen, T., Pierce, G. F., Phillips, M. L.: Matrix-enabled gene transfer for cutaneous wound repair. Wound Repair Regen 8, 473 (2000)
'Matrix-enabled gene transfer for cutaneous wound repair ' () 8 Wound Repair Regen : 473.
Hollon, T.: Researchers and regulators reflct on first gene therapy death. Nature Medicine 6, 6 (2000)
'Researchers and regulators reflct on first gene therapy death ' () 6 Nature Medicine : 6.
Habib, N. A., Hodgson, H. J., Lemoine, N., Pignatelli, M.: A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad metastatic malignant liver tumours. Hum Gene Ther 10, 2019 (1999)
'A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad metastatic malignant liver tumours ' () 10 Hum Gene Ther : 2019.
Zwacka, R. M., Dunlop, M. G.: Gene therapy for colon cancer. Hematol Oncol Clin North Am 12, 595 (1998)
'Gene therapy for colon cancer ' () 12 Hematol Oncol Clin North Am : 595.
Rosengart, T. K., Lee, L. Y., Patel, S. R., Kligfield, P. D., Okin, P. M., Hackett, N. R., Isom, O. W., Crystal, R. G.: Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg 230, 466 (1999)
'Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA ' () 230 Ann Surg : 466.
Eastham, J. A., Hall, S. J., Seghal, I., Wang, J., Timme, T. L., Yang, G., Connel-Crowley, L., Elledge, S. J., Zhang, W. W., Harper, J. W.: In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55, 5151 (1995)
'In vivo gene therapy with p53 or p21 adenovirus for prostate cancer ' () 55 Cancer Res : 5151.